Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19
Zaki F Aref, Shamardan Ezz Eldin S Bazeed, Mohammed H Hassan, Abeer S Hassan, Alaa Rashad, Rehab G Hassan, Aida A Abdelmaksoud
International Journal of Nanomedicine, doi:10.2147/ijn.s313093
Background: Ivermectin is an FDA-approved broad-spectrum anti-parasitic agent that has been shown to inhibit SARS-CoV-2 replication in vitro. Objective: We aimed to assess the therapeutic efficacy of ivermectin mucoadhesive nanosuspension intranasal spray in treatment of patients with mild COVID-19. Methods: This clinical trial included 114 patients diagnosed as mild COVID-19. Patients were divided randomly into two age and sex-matched groups; group A comprising 57 patients received ivermectin nanosuspension nasal spray twice daily plus the Egyptian protocol of treatment for mild COVID-19 and group B comprising 57 patients received the Egyptian protocol for mild COVID-19 only. Evaluation of the patients was performed depending on improvement of presenting manifestations, negativity of two consecutive pharyngeal swabs for the COVID-19 nucleic acid via rRT-PCR and assessments of hematological and biochemical parameters in the form of complete blood counts, C-reactive protein, serum ferritin and d-dimer which were performed at presentation and 7 days later. Results: Of the included patients confirmed with mild COVID-19, 82 were males (71.9%) and 32 females (28.1%) with mean age 45.1 ± 18.9. In group A, 54 patients (94.7%) achieved 2 consecutive negative PCR nasopharyngeal swabs in comparison to 43 patients (75.4%) in group B with P = 0.004. The durations of fever, cough, dyspnea and anosmia were significantly shorter in group A than group B, without significant difference regarding the duration of gastrointestinal symptoms. Duration taken for nasopharyngeal swab to be negative was significantly shorter in group A than in group B (8.3± 2.8 days versus 12.9 ± 4.3 days; P = 0.0001).
Conclusion: Local use of ivermectin mucoadhesive nanosuspension nasal spray is safe and effective in treatment of patients with mild COVID-19 with rapid viral clearance and shortening the anosmia duration. Clinicaltrials.gov Identifier: NCT04716569; https://clinicaltrials.gov/ct2/show/ NCT04716569.
Disclosure No potential conflicts of interest between authors to be declare.
Dovepress
References
Abdelmaksoud, Ghweil, Hassan, Olfactory disturbances as presenting manifestation among egyptian patients with COVID-19: possible role of zinc, Biol Trace Elem Res,
doi:10.1007/s12011-020-02546-5Alam, Murshed, Bhiuyan, Saber, Alam, A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline, J Bangladesh Coll Phys Surg,
doi:10.3329/jbcps.v38i0.47512Alshweiat, Csóka, Tömösi, Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: preparation, characterization, and in vivo evaluation, Int J Pharm,
doi:10.1016/j.ijpharm.2020.119166Aly, Rahman, Indicators of critical illness and predictors of mortality in COVID-19 patients, Infect Drug Resist,
doi:10.2147/IDR.S261159Alzahrani, Saadeldin, Ahmad, The potential use of mesenchymal stem cells and their derived exosomes as immunomodulatory agents for COVID-19 patients, Stem Cells Int,
doi:10.1155/2020/8835986Aref, TCPDF
Azeem, Ashraf, Rasheed, Anjum, Hameed, Evaluation of cytotoxicity and antiviral activity of ivermectin against newcastle disease virus, Pak J Pharm Sci
Errecalde, Lifschitz, Vecchioli, Safety and pharmacokinetic assessments of a novel ivermectin nasal spray formulation in a pig model, J Pharm Sci,
doi:10.1016/j.xphs.2021.01.017Gallego, Nishiura, Sah, Rodriguez-Morales, The COVID-19 outbreak and implications for the Tokyo 2020 Summer Olympic Games, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101604Ghweil, Hassan, Khodeary, Characteristics, outcomes and indicators of severity for COVID-19 among sample of ESNA Quarantine Hospital's Patients, Egypt: a retrospective study, Infect Drug Resist,
doi:10.2147/IDR.S263489Götz, Magar, Dornfeld, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep,
doi:10.1038/srep23138Jabeen, Khader, Jabeen, A review on the antiparasitic drug ivermectin for various viral infections and possibilities of using it for novel severe acute respiratory syndrome coronavirus 2: new hope to treat coronavirus disease
Ketkar, Yang, Wormser, Wang, Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system, Diagn Microbiol Infect Dis,
doi:10.1016/j.diagmicrobio.2019.03.012Kumar, Singh, Kumari, Current understanding of the influence of environmental factors on SARS-CoV-2 transmission, persistence, and infectivity, Environ Sci Pollut Res Int,
doi:10.1007/s11356-020-12165-1Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, Vivo,
doi:10.21873/invivo.12134Liu, Chen, Lin, Han, Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients, J Infect,
doi:10.1016/j.jinf.2020.03.005Lundberg, Pinkham, Baer, Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce venezuelan equine encephalitis virus replication, Antiviral Res,
doi:10.1016/j.antiviral.2013.10.004Mahase, Covid-19: death rate is 0.66% and increases with age, study estimates, BMJ,
doi:10.1136/bmj.m1327Marhl, Grubelnik, Magdič, Markovič, Diabetes and metabolic syndrome as risk factors for COVID-19, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.05.013Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother,
doi:10.1093/jac/dks147Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study, Chest,
doi:10.1016/j.chest.2020.10.009Rodriguez-Morales, Gallego, Escalera-Antezana, COVID-19 in Latin America: the implications of the first confirmed case in Brazil, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101613Rodriguez-Morales, Sánchez-Duque, Hernández-Botero, Preparación y control dela enfermedad por coronavirus 2019 (COVID-19) en América Latina, Acta Medica Peruana,
doi:10.35663/amp.2020.371.909Saindane, Pagar, Vavia, Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization, Aaps Pharmscitech,
doi:10.1208/s12249-012-9896-yShouman, Hegazy, Nafae, Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: a randomised clinical trial, J Clin Diagn Res,
doi:10.7860/JCDR/2020/46795.0000Siddiqui, Danciu, Ashraf, Plants-derived biomolecules as potent antiviral phytomedicines: new insights on ethnobotanical evidences against coronaviruses, Plants,
doi:10.3390/plants9091244Siddiqui, Jahan, Ashraf, Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2, J Biomol Struct Dyn,
doi:10.1080/07391102.2020.1802345Singh, Gupta, Ghosh, Misra, Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.04.004Surti, Patel, Adnan, Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study, RSC Adv,
doi:10.1039/D0RA06379GWagstaff, Rawlinson, Hearps, Jans, An AlphaScreen ® -based assay for high-throughput screening for specific inhibitors of nuclear import, J Biomol Screen,
doi:10.1177/1087057110390360Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J,
doi:10.1042/BJ20120150Wang, Jin, Ren, Updating the diagnostic criteria of COVID-19 "suspected case" and "confirmed case" is necessary, Mil Med Res,
doi:10.1186/s40779-020-00245-9Xia, Quan, Piao, Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability, Eur J Pharm Sci,
doi:10.1016/j.ejps.2010.04.006Yang, Zheng, Gou, Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis, Int J Infect Dis,
doi:10.1016/j.ijid.2020.03.017Zhang, Wang, Jia, Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China, Clin Microbiol Infect,
doi:10.1016/j.cmi.2020.04.012DOI record:
{
"DOI": "10.2147/ijn.s313093",
"ISSN": [
"1178-2013"
],
"URL": "http://dx.doi.org/10.2147/IJN.S313093",
"author": [
{
"ORCID": "http://orcid.org/0000-0002-1803-735X",
"affiliation": [],
"authenticated-orcid": true,
"family": "Aref",
"given": "Zaki F",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0001-7653-0006",
"affiliation": [],
"authenticated-orcid": true,
"family": "Bazeed",
"given": "Shamardan Ezz Eldin S",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0003-2698-9438",
"affiliation": [],
"authenticated-orcid": true,
"family": "Hassan",
"given": "Mohammed H",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-8984-2957",
"affiliation": [],
"authenticated-orcid": true,
"family": "Hassan",
"given": "Abeer S",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Rashad",
"given": "Alaa",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Hassan",
"given": "Rehab G",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Abdelmaksoud",
"given": "Aida A",
"sequence": "additional"
}
],
"container-title": "International Journal of Nanomedicine",
"container-title-short": "IJN",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
6,
14
]
],
"date-time": "2021-06-14T20:46:25Z",
"timestamp": 1623703585000
},
"deposited": {
"date-parts": [
[
2021,
6,
14
]
],
"date-time": "2021-06-14T20:46:39Z",
"timestamp": 1623703599000
},
"indexed": {
"date-parts": [
[
2024,
4,
8
]
],
"date-time": "2024-04-08T17:19:13Z",
"timestamp": 1712596753713
},
"is-referenced-by-count": 36,
"issued": {
"date-parts": [
[
2021,
6
]
]
},
"language": "en",
"license": [
{
"URL": "http://creativecommons.org/licenses/by-nc/3.0/",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
6,
1
]
],
"date-time": "2021-06-01T00:00:00Z",
"timestamp": 1622505600000
}
}
],
"link": [
{
"URL": "https://www.dovepress.com/getfile.php?fileID=70515",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://www.dovepress.com/getfile.php?fileID=70515",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "301",
"original-title": [],
"page": "4063-4072",
"prefix": "10.2147",
"published": {
"date-parts": [
[
2021,
6
]
]
},
"published-online": {
"date-parts": [
[
2021,
6
]
]
},
"publisher": "Informa UK Limited",
"reference": [
{
"DOI": "10.1007/s11356-021-12553-1",
"doi-asserted-by": "crossref",
"key": "ref1",
"unstructured": "El-Sayed, A., Kamel, M. Coronaviruses in humans and animals: the role of bats in viral evolution. Environ Sci Pollut Res. 2021;28:19589–19600. doi:10.1007/s11356-021-12553-1"
},
{
"DOI": "10.1208/s12248-007-9000-9",
"author": "González Canga",
"doi-asserted-by": "publisher",
"first-page": "42",
"journal-title": "AAPS J",
"key": "ref2",
"volume": "10",
"year": "2008"
},
{
"DOI": "10.1038/srep23138",
"author": "Götz",
"doi-asserted-by": "publisher",
"first-page": "23138",
"journal-title": "Sci Rep",
"key": "ref3",
"volume": "6",
"year": "2016"
},
{
"DOI": "10.1042/BJ20120150",
"author": "Wagstaff",
"doi-asserted-by": "publisher",
"first-page": "851",
"journal-title": "Biochem J",
"key": "ref4",
"volume": "443",
"year": "2012"
},
{
"DOI": "10.1080/07391102.2020.1802345",
"author": "Siddiqui",
"doi-asserted-by": "publisher",
"first-page": "1",
"journal-title": "J Biomol Struct Dyn",
"key": "ref5",
"year": "2020"
},
{
"DOI": "10.3390/plants9091244",
"author": "Siddiqui",
"doi-asserted-by": "publisher",
"first-page": "1244",
"journal-title": "Plants",
"key": "ref6",
"volume": "9",
"year": "2020"
},
{
"DOI": "10.1039/D0RA06379G",
"author": "Surti",
"doi-asserted-by": "publisher",
"first-page": "37707",
"journal-title": "RSC Adv",
"key": "ref7",
"volume": "10",
"year": "2020"
},
{
"DOI": "10.1155/2020/8835986",
"author": "Alzahrani",
"doi-asserted-by": "publisher",
"first-page": "8835986",
"journal-title": "Stem Cells Int",
"key": "ref8",
"volume": "2020",
"year": "2020"
},
{
"DOI": "10.1177/1087057110390360",
"author": "Wagstaff",
"doi-asserted-by": "publisher",
"first-page": "192",
"journal-title": "J Biomol Screen",
"key": "ref9",
"volume": "16",
"year": "2011"
},
{
"DOI": "10.1016/j.antiviral.2020.104787",
"author": "Caly",
"doi-asserted-by": "publisher",
"first-page": "104787",
"journal-title": "Antiviral Res",
"key": "ref10",
"volume": "178",
"year": "2020"
},
{
"DOI": "10.1016/j.diagmicrobio.2019.03.012",
"author": "Ketkar",
"doi-asserted-by": "publisher",
"first-page": "38",
"journal-title": "Diagn Microbiol Infect Dis",
"key": "ref11",
"volume": "95",
"year": "2019"
},
{
"DOI": "10.1016/j.ijpharm.2020.119166",
"author": "Alshweiat",
"doi-asserted-by": "publisher",
"first-page": "119166",
"journal-title": "Int J Pharm",
"key": "ref12",
"volume": "579",
"year": "2020"
},
{
"DOI": "10.2174/0929867326666190827151741",
"author": "Alshweiat",
"doi-asserted-by": "publisher",
"first-page": "6459",
"journal-title": "Curr Med Chem",
"key": "ref13",
"volume": "26",
"year": "2019"
},
{
"DOI": "10.21873/invivo.12134",
"author": "Lehrer",
"doi-asserted-by": "publisher",
"first-page": "3023",
"journal-title": "In Vivo",
"key": "ref14",
"volume": "34",
"year": "2020"
},
{
"DOI": "10.1016/j.tmaid.2020.101613",
"author": "Rodriguez-Morales",
"doi-asserted-by": "publisher",
"first-page": "101613",
"journal-title": "Travel Med Infect Dis",
"key": "ref15",
"volume": "35",
"year": "2020"
},
{
"DOI": "10.35663/amp.2020.371.909",
"author": "Rodriguez-Morales",
"doi-asserted-by": "publisher",
"first-page": "3",
"journal-title": "Acta Medica Peruana",
"key": "ref16",
"volume": "37",
"year": "2020"
},
{
"DOI": "10.1016/j.tmaid.2020.101604",
"author": "Gallego",
"doi-asserted-by": "publisher",
"first-page": "101604",
"journal-title": "Travel Med Infect Dis",
"key": "ref17",
"volume": "2020",
"year": "2020"
},
{
"DOI": "10.1007/s12011-020-02546-5",
"author": "Abdelmaksoud",
"doi-asserted-by": "publisher",
"first-page": "1",
"journal-title": "Biol Trace Elem Res",
"key": "ref18",
"year": "2021"
},
{
"DOI": "10.1186/s40779-020-00245-9",
"author": "Wang",
"doi-asserted-by": "publisher",
"first-page": "1",
"journal-title": "Mil Med Res",
"key": "ref19",
"volume": "7",
"year": "2020"
},
{
"DOI": "10.1186/s13613-020-00661-z",
"author": "Li",
"doi-asserted-by": "publisher",
"first-page": "45",
"journal-title": "Ann Intensive Care",
"key": "ref20",
"volume": "10",
"year": "2020"
},
{
"DOI": "10.1016/j.cmi.2020.04.012",
"author": "Zhang",
"doi-asserted-by": "publisher",
"first-page": "767",
"journal-title": "Clin Microbiol Infect",
"key": "ref21",
"volume": "26",
"year": "2020"
},
{
"key": "ref22",
"unstructured": "Ministry of Health and Population. Egyptian national guidelines for COVID-19. 2020. Available online: https://hiph.alexu.edu.eg/images/egyptian_national_guidelines_covid-19.pdf. Accessed December 1, 2020."
},
{
"DOI": "10.1016/j.ejps.2010.04.006",
"author": "Xia",
"doi-asserted-by": "publisher",
"first-page": "325",
"journal-title": "Eur J Pharm Sci",
"key": "ref23",
"volume": "40",
"year": "2010"
},
{
"DOI": "10.21608/AEJI.2020.93432",
"author": "Hegazy",
"doi-asserted-by": "publisher",
"first-page": "93",
"journal-title": "Afro-Egypt J Infect Endem Dis",
"key": "ref24",
"volume": "10",
"year": "2020"
},
{
"DOI": "10.1093/jac/dks147",
"author": "Mastrangelo",
"doi-asserted-by": "publisher",
"first-page": "1884",
"journal-title": "J Antimicrob Chemother",
"key": "ref25",
"volume": "67",
"year": "2012"
},
{
"DOI": "10.1016/j.antiviral.2013.10.004",
"author": "Lundberg",
"doi-asserted-by": "publisher",
"first-page": "662",
"journal-title": "Antiviral Res",
"key": "ref26",
"volume": "100",
"year": "2013"
},
{
"author": "Azeem",
"first-page": "597",
"journal-title": "Pak J Pharm Sci",
"key": "ref27",
"volume": "28",
"year": "2015"
},
{
"DOI": "10.22159/ajpcr.2020.v13i8.38357",
"author": "Jabeen",
"doi-asserted-by": "publisher",
"first-page": "21",
"journal-title": "Asian J Pharm Clin Res",
"key": "ref28",
"volume": "13",
"year": "2020"
},
{
"DOI": "10.2147/IDR.S263489",
"author": "Ghweil",
"doi-asserted-by": "publisher",
"first-page": "2375",
"journal-title": "Infect Drug Resist",
"key": "ref29",
"volume": "13",
"year": "2020"
},
{
"DOI": "10.1016/j.jinf.2020.03.005",
"author": "Liu",
"doi-asserted-by": "publisher",
"journal-title": "J Infect",
"key": "ref30",
"year": "2020"
},
{
"DOI": "10.1136/bmj.m1327",
"author": "Mahase",
"doi-asserted-by": "publisher",
"first-page": "m1327",
"journal-title": "BMJ",
"key": "ref31",
"volume": "369",
"year": "2020"
},
{
"DOI": "10.1016/j.ijid.2020.03.017",
"author": "Yang",
"doi-asserted-by": "publisher",
"first-page": "91",
"journal-title": "Int J Infect Dis",
"key": "ref32",
"volume": "94",
"year": "2020"
},
{
"DOI": "10.1007/s11356-020-12165-1",
"author": "Kumar",
"doi-asserted-by": "publisher",
"first-page": "6267",
"journal-title": "Environ Sci Pollut Res Int",
"key": "ref33",
"volume": "28",
"year": "2021"
},
{
"DOI": "10.2147/IDR.S261159",
"author": "Aly",
"doi-asserted-by": "publisher",
"first-page": "1995",
"journal-title": "Infect Drug Resist",
"key": "ref34",
"volume": "13",
"year": "2020"
},
{
"DOI": "10.1016/j.dsx.2020.05.013",
"author": "Marhl",
"doi-asserted-by": "publisher",
"first-page": "671",
"journal-title": "Diabetes Metab Syndr",
"key": "ref35",
"volume": "14",
"year": "2020"
},
{
"DOI": "10.1016/j.dsx.2020.04.004",
"author": "Singh",
"doi-asserted-by": "publisher",
"first-page": "303",
"journal-title": "Diabetes Metab Syndr",
"key": "ref36",
"volume": "14",
"year": "2020"
},
{
"DOI": "10.7860/JCDR/2020/46795.0000",
"author": "Shouman",
"doi-asserted-by": "publisher",
"journal-title": "J Clin Diagn Res",
"key": "ref37",
"year": "2021"
},
{
"DOI": "10.3329/jbcps.v38i0.47512",
"author": "Alam",
"doi-asserted-by": "publisher",
"first-page": "10",
"journal-title": "J Bangladesh Coll Phys Surg",
"key": "ref38",
"volume": "38",
"year": "2020"
},
{
"DOI": "10.1016/j.chest.2020.10.009",
"author": "Rajter",
"doi-asserted-by": "publisher",
"first-page": "85",
"journal-title": "Chest",
"key": "ref39",
"volume": "159",
"year": "2021"
},
{
"DOI": "10.1208/s12249-012-9896-y",
"author": "Saindane",
"doi-asserted-by": "publisher",
"first-page": "189",
"journal-title": "Aaps Pharmscitech",
"key": "ref40",
"volume": "14",
"year": "2013"
},
{
"DOI": "10.1016/j.xphs.2021.01.017",
"author": "Errecalde",
"doi-asserted-by": "publisher",
"first-page": "2501",
"journal-title": "J Pharm Sci",
"key": "ref41",
"volume": "110",
"year": "2021"
}
],
"reference-count": 41,
"references-count": 41,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.dovepress.com/clinical-biochemical-and-molecular-evaluations-of-ivermectin-mucoadhes-peer-reviewed-fulltext-article-IJN"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Organic Chemistry",
"Drug Discovery",
"General Medicine",
"Biomaterials",
"Bioengineering",
"Biophysics",
"Pharmaceutical Science"
],
"subtitle": [],
"title": "Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19",
"type": "journal-article",
"volume": "Volume 16"
}
